Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects
X Wang, J Wang, S Arora, L Hughes… - The Journal of …, 2019 - Wiley Online Library
Rolapitant (Varubi) is a neurokinin‐1 receptor antagonist approved for the prevention of
chemotherapy‐induced nausea and vomiting. Rolapitant is primarily metabolized by the …
chemotherapy‐induced nausea and vomiting. Rolapitant is primarily metabolized by the …
Initiatives to improve control, resource use, and quality of life associated with chemotherapy-induced nausea and vomiting
M Aapro, R Tarricone - EUROPEAN MEDICAL JOURNAL, 2020 - iris.unibocconi.it
Patients indicate that among the most feared side effects of cancer are chemotherapy-
induced nausea and vomiting (CINV), with up to 80% of patients affected if appropriate …
induced nausea and vomiting (CINV), with up to 80% of patients affected if appropriate …
The clinical problem of chemotherapy-induced nausea and vomiting
B Rapoport - Oncology, 2016 - go.gale.com
Over the past 2 decades, substantial advances have been made in the management of
chemotherapy-induced nausea and vomiting (CINV). This is primarily because of a deeper …
chemotherapy-induced nausea and vomiting (CINV). This is primarily because of a deeper …
Netupitant, a Potent and Highly Selective NK1 Receptor Antagonist, Alleviates Acetic Acid-Induced Bladder Overactivity in Anesthetized Guinea-Pigs
S Palea, V Guilloteau, M Rekik, E Lovati… - Frontiers in …, 2016 - frontiersin.org
Introduction. Tachykinins potently contract the isolated urinary bladder from a number of
animal species and play an important role in the regulation of the micturition reflex. On the …
animal species and play an important role in the regulation of the micturition reflex. On the …
[PDF][PDF] Chemotherapy-induced nausea and vomiting: strategies for prevention and treatment
LS Schwartzberg - Clin Adv Hematol Oncol, 2017 - hematologyandoncology.net
LS A great deal is known about the pathophysiology of chemotherapy-induced nausea and
vomiting (CINV). Several neurotransmitters are involved in the sensation of nausea and the …
vomiting (CINV). Several neurotransmitters are involved in the sensation of nausea and the …
[HTML][HTML] T 罗拉匹坦关键中间体的合成
叶海伟, 王志坚, 高立军, 周丽萍, 陈云华… - 西北大学学报自然科学 …, 2017 - html.rhhz.net
合成一种罗拉匹坦关键中间体(S)-1-((R)-1-(3, 5-二(三氟甲基) 苯基) 乙氧基)-3-氧-2-苯基丙烷-2-
基) 氨基甲酸苄酯(1). 以N-Cbz-L-苯甘氨酸(2) 与苯甲醛二甲缩醛(3) 为原料 …
基) 氨基甲酸苄酯(1). 以N-Cbz-L-苯甘氨酸(2) 与苯甲醛二甲缩醛(3) 为原料 …
Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Cancer Receiving Carboplatin: A Retrospective Study
I Nasu, R Shimano, H Kawazoe, T Nakamura… - Clinical Therapeutics, 2020 - Elsevier
Purpose This study aimed to identify patient-related risk factors for chemotherapy-induced
nausea and vomiting (CINV) in patients with cancer receiving carboplatin in addition to …
nausea and vomiting (CINV) in patients with cancer receiving carboplatin in addition to …
Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting
O Abdel-Rahman, M Fouad - Future Oncology, 2016 - Taylor & Francis
Background: We conducted a pooled analysis of rolapitant-containing regimens versus
control in the prophylaxis of chemotherapy-induced nausea and vomiting. Methodology …
control in the prophylaxis of chemotherapy-induced nausea and vomiting. Methodology …